Nektar amends bylaws for universal proxy rules, DGCL updates, and remote meetings

NEKTAR THERAPEUTICS

Board approved bylaw amendments effective Dec 15, 2022, to comply with SEC universal proxy rules and recent DGCL changes.
Stockholder nominations now require representation of intent to solicit at least 67% voting power.
Company may hold meetings solely by remote communication; proxy cards for board nominees must be white.
Enhanced disclosure requirements for stockholder proposals and director nominations added.
Proxies for disqualified or withdrawn nominees to be treated as abstentions.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

NEKTAR THERAPEUTICS: Amended the Amended and Restated Bylaws to reflect changes in DGCL, adopt universal proxy rules, and enhance stockholder proposal requirements (effective 2022-12-15).

Change: bylaw amendment
Effective: 2022-12-15

Exact text from the filing

On December 15, 2022, in connection with the new Securities and Exchange Commission rules and changes to the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of corporate governance matters, the Board of Directors (the “Board”) of Nektar Therapeutics (the “Company”), approved amendments to the Company’s Amended and Restated Bylaws (the “Bylaws”), effective immediately.

View on SEC.gov

27 governance changes filed in the last 30 days. Browse all governance changes →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-22-080498

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.